看见一个 Expert Review of Anticancer Therapy。你们前面用依维莫斯,血、肝肾功能还好。下一步是否考虑索拉非尼+依维莫斯。供你参考。8 j4 F. u1 X5 t
$ H! p: l8 p. E
% h4 T9 A! S& V0 ~! A! T6 FCurrently available feasibility data for possible combination strategies. h- J3 u2 h( e
————————————————————————————————4 U- Y3 d7 o' j; Z# L6 a& A
Combination Feasibility according to preliminary data 9 A' \( i6 {; U
——————————————————————————————————
/ h1 ~% B( w9 V8 aBevacizumab + sorafenib Yes, reduced dose % @7 N1 I$ {9 P% E
Bevacizumab + sunitinib† No % Z3 t: y1 F- C' k1 }
Bevacizumab + temsirolimus Yes
1 |3 o/ k0 r- M9 ?/ }% u2 RBevacizumab + everolimus Yes
$ ]/ M# H% q: _: B- Z$ gSorafenib + sunitinib ? * h! L: F4 {3 k; b
Sorafenib + temsirolimus Yes, reduced dose
8 Q0 d# j; S0 y, d& O# LSorafenib + everolimus Yes, reduced dose ) w) o& G8 h# I- `+ `
Sunitinib + temsirolimus† No
9 d0 r% K& `$ I1 g) S, oSunitinib + everolimus ?
3 N" M3 r2 Z$ ^+ ?Temsirolimus + everolimus ?
; _( ]( n! V6 G3 r% x8 ]* {1 ^" f————————————————————
$ j, X( _" M& E: F†Led to US FDA warning.
% a" }) X: x. W @8 n! z4 P?: As yet unattempted combination.
9 ]. l2 n7 } O/ F9 N# }2 E0 u |